Join        Login             Stock Quote

Ligand Pharma (LGND) Receives Equity Milestone Payment From Retrophin

 January 09, 2013 12:28 PM

(By Balaseshan) Ligand Pharmaceuticals Inc. (NASDAQ: LGND) said it has received a milestone payment of 620,000 shares of common stock in newly public partner Desert Gateway Inc.'s unit (PINK: RTRX) Retrophin Inc.

The milestone arose under the previously executed license agreement for the development and commercialization of Retrophin's lead clinical candidate RE-021, formerly known as DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors).

The clinical candidate RE-021 was triggered by the completion of Retrophin's merger with Desert Gateway and its transition to a publicly traded company.

[Related -Six Stocks That Could Get An October Bump From The FDA]

Ligand will record milestone revenue equal to the estimated fair value of the shares received, which will be determined by an independent valuation firm. The shares issued to Ligand represent about 7% of Retrophin's outstanding capital stock and may be subject to certain trading restrictions.

RE-021 is in development for the treatment of focal segmental glomerulosclerosis (FSGS), a rare disease that attacks the kidney's filtering system (glomeruli), causing serious scarring, progressive kidney function degeneration and rapid loss of the kidneys. FSGS is one cause of a serious condition known as Nephrotic Syndrome.

An estimated 50,000 patients in the U.S. suffer from FSGS, with most patients diagnosed as children or young adults. Ligand believes that Retrophin expects to begin enrollment in a Phase 2 clinical trial known as "FONT-3" during the first half of 2013.

[Related -Futures Gain After Claims Data; Amazon.Com (AMZN) Drops]

LGND is trading up 5.70% at $20.60 on Wednesday. The stock has been trading between $11.21 and $21.75 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageLong-term Relationships and Credit Scores

Unlike many commentators, I tend to think credit scores are a good read on...

article imageIn Defense Of Rolling Return Charts

Robeco’s Lukas Daalder has a bit of an issue with rolling-performance graphics. Bashing a recent chart of read on...

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.